What Is the Downside to Taking GLP-1 for Weight Loss? 6 Trade-Offs to Know

A person holding a glass of water beside a GLP-1 weight loss injection pen, illustrating the hydration trade-offs of GLP-1 medications

The main downsides of taking a GLP-1 medication for weight loss are gastrointestinal side effects, loss of lean muscle along with fat, weight regain once you stop, a short list of rarer but serious risks on the FDA label, and cost. In the pivotal semaglutide trial, 44% of participants reported nausea and 30% reported diarrhea, and about 25% of the weight lost on tirzepatide came from lean mass rather than fat. Most of these trade-offs are manageable, but two of them — dehydration and constipation — hinge directly on something people rarely plan for: how much water you actually drink.

That last point is why we cover GLP-1 medications on a water-quality site. The drugs slow how fast your stomach empties, which is the whole point of how they work. That same mechanism blunts thirst, and when nausea or vomiting is added on top, fluid losses stack up quickly. Understanding the downsides means understanding the fluid side of them.

Some links below are affiliate links. If you buy through them we may earn a commission at no extra cost to you. See our Affiliate Disclosure.

The 6 real downsides of GLP-1 medications

1. Gastrointestinal side effects are common, not rare

This is the downside most people meet first. In the FDA prescribing information for Wegovy (semaglutide 2.4 mg), nausea was reported by 44% of treated patients versus 16% on placebo, vomiting by 25% versus 6%, and diarrhea by 30% versus 16%. Constipation showed up in roughly 24% of semaglutide participants in the STEP 1 trial, compared with 11% on placebo.

Tirzepatide (Zepbound, Mounjaro) shows a similar pattern. In SURMOUNT-1, adverse events led 4.3% to 7.1% of participants to stop treatment depending on dose, against 2.6% on placebo. For Wegovy, 6.8% of patients discontinued permanently because of adverse reactions versus 3.2% on placebo, with nausea, vomiting, and diarrhea the leading reasons.

The honest read: for most people these symptoms are worst during dose escalation and settle down. For a meaningful minority — roughly 1 in 15 — they are bad enough to end treatment.

2. Dehydration, and the kidney risk behind it

This is the downside that gets underestimated. The FDA prescribing information for semaglutide states that a majority of reported post-marketing acute kidney injury cases occurred in patients who had experienced nausea, vomiting, or diarrhea leading to volume depletion. In other words, the kidney events were largely a dehydration problem, not a direct drug-toxicity problem.

A pharmacovigilance analysis of FDA Adverse Event Reporting System data from 2004 through 2021, published in Frontiers in Endocrinology, identified 2,670 acute kidney injury cases associated with GLP-1 receptor agonists, with a hospitalization rate of 45.3% and a median time to onset of 63 days. These are voluntary reports, so they cannot establish how often this happens per patient — but they do tell you which mechanism keeps recurring.

FDA labeling advises clinicians to monitor kidney function in patients reporting reactions that could cause severe dehydration, particularly at initiation and dose escalation. That is the window to be deliberate about fluids.

We wrote a fuller breakdown of the warning signs in what happens if you don’t drink enough water on GLP-1, and a practical target-setting guide in how much water to drink on Zepbound.

A glass of water and a tape measure on a kitchen counter, illustrating the hydration habits that help manage GLP-1 weight loss side effects

3. You lose muscle along with fat

Weight loss is not the same as fat loss. A DXA body-composition analysis from the SURMOUNT-1 study, published in Diabetes, Obesity and Metabolism, found that participants on the highest tirzepatide dose lost 21.3% of body weight overall — a 33.9% reduction in fat mass and a 10.9% reduction in lean mass. That works out to roughly a quarter of the total weight lost coming from lean tissue.

Some lean-mass loss accompanies any substantial weight loss, including diet-only and surgical weight loss. But the pace matters. Resistance training and adequate protein are the standard counter-measures, and they are worth building in from week one rather than after the fact.

4. The weight comes back if you stop

The STEP 1 trial extension, published in Diabetes, Obesity and Metabolism, followed participants after semaglutide and the structured lifestyle program were both withdrawn. Mean weight loss at week 68 was 17.3% on semaglutide versus 2.0% on placebo. By week 120 — a year after withdrawal — the semaglutide group had regained 11.6 percentage points, leaving a net 5.6% below baseline. Roughly two-thirds of the loss came back.

Cardiometabolic improvements largely reverted toward baseline over that same period. STEP 4, published in JAMA, showed the flip side: participants who stayed on the drug after a 20-week run-in kept losing, while those switched to placebo regained steadily over the next 48 weeks.

The practical implication is that these are maintenance medications, not a course of treatment with an end date. The NIH’s NIDDK puts it plainly: after stopping any weight-management medication, you probably will regain some weight.

5. Rarer but serious labeled risks

These are uncommon, but they are on the label for a reason:

  • Thyroid C-cell tumors (boxed warning). In rodent studies, semaglutide caused a dose- and duration-dependent increase in thyroid C-cell tumors. Whether this translates to humans is unknown. The drug is contraindicated if you or a family member has had medullary thyroid carcinoma or MEN 2.
  • Gallbladder disease. The Wegovy label reports cholelithiasis in 1.6% of treated patients versus 0.7% on placebo, and cholecystitis in 0.6% versus 0.2% — and notes the excess was not fully explained by the degree of weight loss.
  • Pancreatitis. Labels for both semaglutide and tirzepatide direct clinicians to stop the drug promptly if pancreatitis is suspected. In tirzepatide’s SURPASS program, adjudicated pancreatitis incidence was roughly 0.3% — similar to placebo.
  • Severe gastrointestinal reactions. Reported in 4.1% of Wegovy patients versus 0.9% on placebo. Labels have been updated over time to reflect post-marketing gastrointestinal reports, including intestinal blockage.

None of this is a reason to avoid the medication on its own. It is a reason to have the conversation with a prescriber rather than sourcing it from a website.

6. Cost and coverage

List prices for the branded weight-loss GLP-1s run around $1,000 or more per month in the United States, and coverage is inconsistent. In KFF’s 2025 employer survey, 19% of large firms (200+ workers) covered GLP-1s specifically for weight loss in their largest plan; among firms with 5,000+ employees that rose to 43%. Standard Medicare Part D does not cover these drugs when prescribed solely for weight loss, though CMS is running a time-limited GLP-1 access demonstration. Since stopping brings the weight back, the cost question is an indefinite one, not a one-year one.

How to blunt the hydration-linked downsides

Two of the six downsides above — dehydration-linked kidney risk and constipation — respond directly to fluid intake. A few things that help:

  • Drink on a schedule, not on thirst. Delayed gastric emptying dulls the thirst signal. Sipping to a set routine works better than waiting to feel dry.
  • Small volumes, spread out. Large boluses on a slow-emptying stomach make nausea worse. Frequent small amounts are better tolerated.
  • Add electrolytes when you are losing fluid. If vomiting or diarrhea is in the picture, plain water alone replaces volume but not sodium and potassium. We compared the options in electrolyte water vs regular water; a sugar-free electrolyte powder is the simplest way to do this without adding calories.
  • Fix the taste problem. Many people simply do not drink enough because their tap water tastes of chlorine. That is a solvable problem — a carbon filter pitcher or an under-sink system from Aquasana or Crystal Quest removes the chlorine taste and makes hitting a daily target far easier.
  • Know what is actually in your water. If you are drinking noticeably more water every day, it is worth knowing its contaminant profile. A certified lab test from Tap Score gives you real numbers, and our drinking water quality by state hub shows what is typical where you live.

For the broader picture on fluids and weight loss, see our pillar guide to water for weight loss and GLP-1, and the first-month checklist in what I wish I knew before starting GLP-1.

Before you drink more, know what you’re drinking

If you’ve been increasing your water intake, it’s worth knowing what’s actually coming out of your tap. Your utility’s annual report covers the whole system average, not your house — and it says nothing at all about private wells or your own plumbing. A certified lab test gives you a full contaminant panel and, just as often, tells you your water is fine and you don’t need to buy anything.

Frequently asked questions

What is the biggest downside of GLP-1 medications?

For most people it is gastrointestinal side effects — nausea affected 44% of participants in the semaglutide weight-loss trials. But the downside with the longest tail is weight regain: the STEP 1 extension found roughly two-thirds of lost weight returned within a year of stopping.

Do GLP-1 drugs damage your kidneys?

The FDA label attributes the majority of reported post-marketing acute kidney injury cases to volume depletion from nausea, vomiting, or diarrhea — that is, to dehydration rather than direct kidney toxicity. Staying ahead of fluid losses is the practical protection. If you have existing kidney disease, this is a conversation to have with your prescriber before starting.

Why do GLP-1 medications cause constipation?

These drugs slow gastric emptying and gut motility, so stool spends longer in the colon and more water is reabsorbed from it. Constipation was reported by about 24% of semaglutide participants in STEP 1 versus 11% on placebo. Fluid, gradual fiber increases, and movement are the usual first-line responses.

How much muscle do you lose on a GLP-1?

In the SURMOUNT-1 body-composition analysis, participants on the highest tirzepatide dose lost 10.9% of lean mass alongside a 33.9% reduction in fat mass — roughly a quarter of total weight lost was lean tissue. Resistance training and adequate protein intake are the standard mitigations.

Will I regain the weight if I stop taking a GLP-1?

Most people regain a substantial share of it. In the STEP 1 extension, participants regained 11.6 of the 17.3 percentage points they had lost within a year of stopping the drug and the lifestyle program. NIDDK notes that regain after stopping any weight-management medication should be expected.

Does drinking more water reduce GLP-1 side effects?

Adequate fluid intake is standard clinical advice for managing the constipation and dehydration risk associated with these drugs, and dehydration is the mechanism the FDA links to reported kidney injury cases. It will not eliminate nausea, which is driven by the drug’s effect on gastric emptying, but it addresses the complications that follow from fluid loss.

Sources

Last updated August 6, 2026.

This article is for general information only and is not medical advice. GLP-1 medications are prescription drugs; decisions about starting, adjusting, or stopping one should be made with a licensed clinician who knows your history. See our Health Disclaimer.

Leave a Reply

Your email address will not be published. Required fields are marked *